Alexza secures $45 million from investors based on U.S. Adasuve sales

Alexza's Staccato device--Courtesy of Alexza

Alexza Pharmaceuticals ($ALXA), commercial partners with Teva Pharmaceutical Industries ($TEVA), raised $45 million from the sale of notes to investors. The Mountain View, CA, company secured the notes by royalties and potential milestones from U.S. sales of Adasuve, an inhaled schizophrenia and bipolar disorder treatment delivered with Alexza's Staccato device. The treatment, a powdered version of loxapine, is currently the only orally inhaled treatment for agitation symptoms associated with these diseases and uses a fast onset of about two minutes to curb an episode. Release

Suggested Articles

Kala Pharma's Eysuvis on Tuesday became the first and only corticosteroid approved to treat short-term signs and symptoms of dry eye disease.

Xeris scored an FDA fast track designation for its diazepam formulation, delivered via autoinjector, to treat acute repetitive seizures.

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.